Eli Lilly Reaches $1 Trillion as Growth Reshapes Valuation

 StocksRunner
 
  StocksRunner
 
Follow  Message
 
 
Find out what happening right now and get all the pieces of the puzzle on important data activity before the major news sources break the story and see what are the trends
 

•  05 Aug 2026
 

$LLY Eli Lilly ended the second quarter with results that explain how a 150 year old pharmaceutical company became worth more than $1 trillion. Revenue surged 48% to $22.97 billion, compared with analyst expectations of $20.73 billion. Adjusted earnings reached $8.38 per share, well above the $6.01 forecast, and the stock rose more than 5% in premarket trading.

The figures are exceptional not only relative to forecasts, but also compared with what is normally seen from a pharmaceutical company of this size. Eli Lilly is expected to generate $85 billion to $87 billion in revenue this year, compared with only $45 billion in 2024 and $65.2 billion in 2025. Within two years, the company is nearly doubling revenue. Compared with 2022, when Mounjaro entered the United States market, revenue is expected to be almost three times higher.

One molecule, tirzepatide, stands behind the transformation and is sold under two commercial names. Mounjaro was approved in May 2022 for type 2 diabetes, while Zepbound was approved in November 2023 for obesity. Both activate the GIP and GLP-1 receptors, help regulate blood sugar levels, and reduce food intake. Medically, they are the same molecule, but commercially Eli Lilly gained access to two enormous markets, diabetes and obesity, which overlap significantly but not completely.

Global Mounjaro sales jumped 91% to $9.94 billion in the latest quarter, compared with a forecast of approximately $9 billion. Zepbound sales in the United States increased 44% to $4.93 billion, compared with expectations of $4.69 billion. Together, the two drugs generated $14.87 billion during the quarter, nearly 65% of company revenue. At the current pace, that represents annual revenue close to $60 billion before further growth in the number of users.

For comparison, combined Mounjaro and Zepbound sales totaled approximately $16.5 billion during all of 2024. In 2025, they reached $36.5 billion. They are now generating in one quarter almost as much revenue as they produced during all of 2024. The market is not seeing only a successful drug launch, but a change in the entire revenue and profit profile of the company.

The revenue surge may create the impression that Eli Lilly can raise prices without limitation, but the opposite is happening. Output of its core products increased 60%, while the average price the company actually received fell 13%. Eli Lilly is selling far more doses while receiving less money for each one. As long as the gap between those two rates remains wide, revenue continues to expand rapidly.

United States revenue increased 33% to $14.4 billion, driven by a 37% increase in unit volume. Revenue outside the United States jumped 80% to $8.6 billion, while volume rose 113% and realized pricing fell 36%. Part of the price decline reflects the inclusion of Mounjaro in government coverage in China, alongside insurer discounts and price reductions for direct paying customers.

The pricing pressure is not only erosion that the company is forced to accept, but to some extent a strategic decision. Lower prices expand insurance coverage, increase the number of patients, and make it more difficult for new competitors to enter the market. Eli Lilly can afford the strategy because demand is high and manufacturing capacity is increasing. The risk is that revenue growth could slow quickly if volume growth weakens while pricing continues to decline.

Demand for Mounjaro and Zepbound was high almost from the moment they reached the market, but for an extended period the problem was not finding customers. It was producing enough doses. Tirzepatide products entered the FDA shortage list at the end of 2022. Eli Lilly responded with tens of billions of dollars in investments in factories and filling lines, mainly in the United States.

Those investments are important for understanding the valuation. A pharmaceutical company that develops a successful treatment is not necessarily capable of serving a market containing tens of millions of patients. For injectable drugs, manufacturing capacity, pens, raw materials, and packaging lines become competitive barriers. Eli Lilly does not only own a highly demanded drug, but is building a system capable of producing and distributing it on a global scale.

Expanding production also allows the company to lower prices without giving up revenue growth. If every dose generates less revenue, the company must sell many more doses to offset the decline. The 60% increase in output during the quarter provided that offset. It also requires heavy capital investment before the associated revenue arrives.

The $1 trillion valuation is not based only on Mounjaro and Zepbound. Investors are also paying for the possibility that Eli Lilly will move patients from injections to pills, expand metabolic drugs into additional diseases, and launch a new generation of treatments. These future products are part of the earnings momentum embedded in the current valuation.

Foundayo, the pill approved in the United States in April, generated $98 million in revenue during its first full quarter. That remains a small amount for Eli Lilly and was slightly below expectations, but its strategic importance is greater than the current revenue contribution. A pill can reach patients who fear injections, simplify distribution, and reduce some manufacturing constraints associated with injectable drugs. It also enters a market where Novo Nordisk already has a presence and millions of prescriptions.

Behind Foundayo is retatrutide, an experimental drug that activates three receptors, GIP, GLP-1, and glucagon. In a Phase 3 trial, the highest dose produced an average weight reduction of 28.3% after 80 weeks. The result brings the treatment close to weight loss levels associated with bariatric surgery. If approved and able to reproduce the data in real world use, it could extend Eli Lilly competitive advantage after growth in the current generation begins to moderate.

The same dynamic explains the pace of acquisitions. Eli Lilly is using cash flow generated from diabetes and obesity to purchase assets in oncology, genetic medicine, pain, sleep, and mental health. During the latest quarter, the company recorded approximately $2.8 billion in acquired research and development charges. For accounting purposes, those amounts are recognized immediately as expenses even though the transactions are intended to produce drugs and revenue several years from now.

Eli Lilly trades at a valuation above $1 trillion. The market expects earnings of $34.54 per share this year, producing a forward multiple of approximately 33. Based on the midpoint of the updated company outlook of $36 per share, the multiple is slightly lower at approximately 32. The valuation reflects multiple expansion normally associated with a growth company rather than a mature pharmaceutical business.

Novo Nordisk, the direct competitor, trades at a forward multiple of approximately 13 to 14. Larger and more diversified pharmaceutical companies also normally trade at significantly lower multiples. There are reasons for that difference. Novo Nordisk is dealing with stagnation and even declining revenue, while Eli Lilly is growing 48%.

Investors are not valuing Eli Lilly as a mature pharmaceutical company. They are valuing it as a growth company whose core product is still in the early stages of market penetration. Even strong growth, however, does not make every price reasonable. Consensus expects earnings per share to increase from approximately $34.54 in 2026 to about $45 in 2027, growth of roughly 30%.

That estimate produces a multiple of approximately 26 on next year earnings. Taking the raised outlook into account lowers the multiple to approximately 22 to 23. A multiple of 23 on next year earnings is still not a low valuation. It means the company would continue to trade at a meaningful premium to most of the pharmaceutical sector even after expected earnings growth of about 30%.

The current report gave the market almost everything it could request. Revenue exceeded forecasts by more than $2 billion, adjusted earnings came in approximately 40% above expectations, Mounjaro grew 91%, Zepbound continued expanding, and the annual revenue outlook was raised. At a $1 trillion valuation, strong results are not enough. Eli Lilly must continue delivering upside surprises.

To justify the multiple, Eli Lilly must preserve its advantage over Novo Nordisk, continue increasing production, secure broader insurance coverage, absorb lower pricing without damaging margins, succeed with the pill, and translate retatrutide trial results into approval and sales. It must also demonstrate that its many acquisitions will create additional growth engines rather than only immediate expenses. These conditions determine whether current institutional flows can remain supported.

Eli Lilly reached $1 trillion because for four years the market repeatedly discovered that previous forecasts were too low. Patient numbers increased faster than expected, production expanded, tirzepatide sales grew from tens of millions of dollars to tens of billions, and the pipeline produced candidates capable of extending the growth cycle. The positioning question is whether that sequence can continue at a scale large enough to support the premium valuation.

View all market intelligence